Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes?

Endocrine

Volumn 44, Issue 2, 2013, Pages 343-345

  Esposito, Katherine ^a   Ceriello, Antonio ^b   Giugliano, Dario ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Clinical management; Personalized medicine; Type 2 diabetes; Uncertainty

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA;

ALGORITHM; CARDIOVASCULAR RISK; CLINICAL RESEARCH; DRUG TREATMENT FAILURE; HEALTH CARE QUALITY; HUMAN; HYPERGLYCEMIA; MEDICAL PRACTICE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UNCERTAINTY;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; GOALS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INDIVIDUALIZED MEDICINE; PROFESSIONAL PRACTICE; RISK FACTORS; UNCERTAINTY;

EID: 84885583673     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-9918-x     Document Type: Review

References (22)

1. J. Wennberg, On patient need, equity, supplier-induced demand, and the need to assess the outcome of common medical practice. Med. Care 23, 512-520 (1985)
2. D. Gianakos, Accepting limits. Arch. Intern. Med. 158, 1059-1061 (1998)
3. D. Giugliano, K. Esposito, Clinical inertia as a clinical safeguard. JAMA 305, 1591-1592 (2011)
4. D.R. Whiting, L. Guariguata, C. Weil, J. Shaw, IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 94, 311-321 (2011)
5. W.T. Cefalu, American Diabetes Association-European Association for the study of diabetes position statement: due diligence was conducted. Diabetes Care 35, 1201-1203 (2012)
6. T.J. Hoerger, J.E. Segel, E.W. Gregg, J.B. Saaddine, Is glycemic control improving in U.S. adults? Diabetes Care 31, 81-86 (2008)
7. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A.L. Peters, A. Tsapas, R. Wender, D.R. Matthews, Management of Hyperglycemia in Type 2 Diabetes: a Patient-Centered Approach: position Statement of the American Diabetes Association (ADA) and the European Association for the study of diabetes (EASD). Diabetes Care 35, 1364-1379 (2012)
8. American Diabetes Association, Standards of medical care in diabetes-2013. Diabetes Care 36(Suppl. 1), S11-S66 (2013)
9. K. Esposito, G. Bellastella, D. Giugliano, When metformin fails in type 2 diabetes mellitus. Arch. Intern. Med. 171, 365-366 (2011)
10. D. Giugliano, A. Ceriello, K. Esposito, HbA1c targets for type 2 diabetes: how many, how far! Diabetes Res. Clin. Pract. 96, 414-415 (2012)
11. S. Colagiuri, Optimal management of type 2 diabetes: the evidence S. Diabetes Obes. Metab. 14(Suppl. 1), 3-8 (2012)
12. J. Yeaw, J.S. Benner, J.G. Walt, S. Sian, D.B. Smith, Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15, 728-740 (2009)
13. B. Hemmingsen, S.S. Lund, C. Gluud, A. Vaag, T. Almdal, C. Hemmingsen, J. Wetterslev, Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 343, d6898 (2011)
14. R. Boussageon, T. Bejan-Angoulvant, M. Saadatian-Elahi, S. Lafont, C. Bergeonneau, B. Kassaï, S. Erpeldinger, J.M. Wright, F. Gueyffier, C. Cornu, Effect of intensive glucose lowering treatment on all-cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343, d4169 (2011)
15. D.M. Mann, M. Woodward, F. Ye, M. Krousel-Wood, P. Muntner, Trends in medication use among US adult with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors. Arch. Intern. Med. 169, 1718-1720 (2009)
16. A. Qaseem, L.L. Humphrey, D.E. Sweet, M. Starkey, P. Shekelle, For the Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 156, 218-231 (2012)
17. M.J. Barry, S. Edgman-Levital, Shared decision making - the pinnacle of patient-centered care. N. Engl. J. Med. 366, 780-781 (2012)
18. M.C. Riddle, D.M. Karl, Individualizing targets and tactics for high-risk patients with type 2 diabetes. Practical lessons from ACCORD and other cardiovascular trials. Diabetes Care 35, 2100-2107 (2012)
19. O.J. Phung, J.M. Scholle, M. Talwar, G.I. Coleman, Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 303, 1410-1418 (2010)
20. J.L. Gros, C.K. Kramer, C.B. Leitão, N. Hawkins, L.V. Viana, B.D. Schaan, L.C. Pinto, T.C. Rodrigues, M.J. Azevedo, For the Diabetes and Endocrinology Meta-analysis Group (DEMA). Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann. Intern. Med. 154, 672-679 (2011)
21. K. Esposito, P. Chiodini, G. Bellastella, M.I. Maiorino, D. Giugliano, Proportion of patients at HbA1c target < 7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes. Metab. 14, 228-233 (2012)
22. C.J. Currie, E.A. Gale, C.D. Poole, Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007. Diabet. Med. 27, 938-948 (2010)